The list below contains links to the European Medicines Agency. Through this website, you will find links to the European Public Assessment Report (EPAR) as well as the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC) for our licensed product Translarna (ataluren) ▼.

Please note that this information is specific to the UK and is not intended to replace the advice of a qualified healthcare professional.

Translarna (ataluren) ▼   EPAR
Translarna (ataluren) ▼ 125 mg SPC PIL
Translarna (ataluren) ▼ 250mg SPC PIL
Translarna (ataluren) ▼ 1000mg SPC PIL

 

▼ This medicinal product is subject to additional monitoring. Adverse events (suspected side effects) should be reported. Healthcare professionals and patients are asked to report any suspected adverse events via the Yellow Card Scheme. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events can also be reported to PTC Therapeutics Ltd at medinfo@ptcbio.com

By following this link you will be leaving the ptcbio.co.uk website.

Please note that PTC Therapeutics Limited does not take responsibility for the content displayed on other websites.
Cancel Continue